CLINICAL TRIALS PROFILE FOR CONCERTA
✉ Email this page to a colleague
All Clinical Trials for Concerta
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00069927 ↗ | Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-08-01 | RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help. |
| NCT00069927 ↗ | Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression | Terminated | University of South Florida | Phase 2 | 2003-08-01 | RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help. |
| NCT00151970 ↗ | Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD | Completed | Noven Pharmaceuticals, Inc. | Phase 2 | 2005-06-01 | This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD. |
| NCT00151970 ↗ | Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD | Completed | Noven Therapeutics | Phase 2 | 2005-06-01 | This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Concerta
Condition Name
Clinical Trial Locations for Concerta
Trials by Country
Clinical Trial Progress for Concerta
Clinical Trial Phase
Clinical Trial Sponsors for Concerta
Sponsor Name
| Sponsor Name for Concerta | |
| Sponsor | Trials |
| Massachusetts General Hospital | 14 |
| McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | 13 |
| Ortho-McNeil Janssen Scientific Affairs, LLC | 10 |
| [disabled in preview] | 7 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
